# Digestiva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digestiva

- Industry: Biotechnology
- Headquarters: Davis, US
- Total disclosed funding: $18M
- Latest round: Series A (Jul 2, 2024)
- Investors on record: 4

## About

Established in 2018 by co-founders Glenn Nedwin and Wilson Mark and based in California, US, Digestiva, Inc. is a developer of bioinformatics food nutritional protein with a proprietary class of enzymes for the absorption of amino acids important for human health. In July 2024, Digestiva, Inc. raised USD 18.4 million in Series A funding led by investor Magdalena, with participation from investor The March Fund, Astanor Ventures, and UC Investments. As of July 2024, the company is led by CEO John Melo.


Digestiva's primary products are proprietary enzyme ingredients designed to enhance protein digestion and improve the nutritional value of foods and dietary supplements, such as proprietary enzymes: These enzymes are designed to improve protein digestibility, making proteins accessible and beneficial for the body. Bioactive peptides are produced through precise protein digestion and are intended to amplify essential nutrient pathways in the body. AI-Enabled Enzyme and Bioactive Peptide Discovery: This product line leverages machine learning to identify optimal protease-food pairings, enhancing the nutritional value and physiological effects of foods. The company's products offer various health benefits, including metabolic health, muscle health and strength, healthy development, gut comfort and health, and healthy ageing.


The company will use the July 2024 funding to accelerate its growth and manufacturing initiatives.

## Funding rounds

- Series A, Jul 2, 2024, $18M — The March Group, Astanor Ventures, UC Investments, Magdalena

## Investors

- The March Group (https://capitalatlas.ai/funds/the-march-group) — Series A
- Astanor Ventures (https://capitalatlas.ai/funds/astanor-ventures) — Series A
- UC Investments — Series A
- Magdalena — Series A